GLP-1受体激动剂对鼻窦术后管理的影响评估
本研究为回顾性队列分析,基于TriNetX美国协作网络数据,纳入接受过至少一次FESS的成人CRSwNP合并肥胖患者,比较有或无GLP-1RA处方者1年及5年内翻修手术和首次生物制剂处方的发生率。经1:1倾向匹配后每组1391例,GLP-1RA组翻修FESS风险在1年(RR 0.64)和5年(RR 0.60)均显著降低,5年首次生物制剂处方亦较低(RR 0.72)。
要点
- CRSwNP合并肥胖患者FESS术后使用GLP-1RA与1年及5年翻修手术风险降低相关
- GLP-1RA组5年内首次生物制剂处方风险低于非GLP-1RA组
- 需未来机制性和前瞻性研究确认该关联
核心结论
- GLP-1RA与CRSwNP合并肥胖患者FESS术后长达5年随访中翻修手术减少相关。
研究设计与样本
- 回顾性队列分析,数据来自TriNetX Analytics平台的美国协作网络。
- 纳入接受过至少一次FESS的成人CRSwNP合并肥胖患者,比较有或无GL-1RA处方者。
- 经1:1倾向匹配后每组1391例。
临床怎么用
- 对于CRSwNP合并肥胖且拟行或已行FESS的患者,GLP-1RA处方可能与降低翻修手术和生物制剂使用风险相关。
局限性
- 回顾性研究设计,可能存在未测量混杂。
- 需未来机制性和前瞻性研究确认关联。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Emerging evidence suggests a potential association between chronic rhinosinusitis (CRS) and obesity. With the increasing utilization of weight loss medications in the management of obesity, we aimed to assess the impact of glucagon-like peptide-1 receptor agonist (GLP-1RA) prescription on the revision rate of functional endoscopic sinus surgery (FESS) and the use of biologics post-FESS. STUDY DESIGN: Retrospective cohort analysis. SETTING: US Collaborative Network within the TriNetX Analytics platform. METHODS: We queried the TriNetX Analytics platform for all adult CRS with nasal polyps (CRSwNP) patients with obesity who have undergone at least one prior FESS (based on Current Procedural Terminology [CPT] code). The incidence of revision surgery and first-time biologic prescriptions (dupilumab, mepolizumab, and omalizumab) within a 1- and 5-year follow-up period was assessed, comparing those with and without GLP-1R agonist prescriptions. RESULTS: After 1:1 propensity matching, there were a total of 1391 patients in each patient group. The GLP-1RA cohort had a significantly reduced incidence of revision FESS compared to the non-GLP-1RA cohort at 1-year (RR: 0.64; 95% CI: 0.41-0.98, P = .04) and 5-year follow-up periods (risk ratio [RR]: 0.60; 95% CI: 0.44-0.0.81, P = .001). At the 5-year follow-up, the first-time biologic prescription was lower in the GLP-1RA cohort compared to the non-GLP-1RA cohort (RR: 0.72; 95% CI: 0.52-0.98, P = .04). CONCLUSION: Our results indicate that GLP-1RAs are associated with reduced postoperative revision FESS at up to a 5-year follow-up in CRSwNP patients. Future mechanistic and prospective studies are needed to confirm the association between GLP-1R agonists and improved post-sinus surgery outcomes identified in this study.
引用
- Hoying D, Kaelber DC, Chaaban MR, et al. Assessing the Impact of GLP-1R Agonists in Post-sinus Surgery Management. Otolaryngol Head Neck Surg. 2025. PMID: 41353729. doi:10.1002/ohn.70072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。